Your trusted source for investing success

Tag: clinical trials

InspireMD Announces Distribution Agreement for MGuard Prime™ in Chile

InspireMD (NYSE:NSPR) has announced it has signed an agreement with CorpMedical Chile Ltda to distribute the MGuard Prime Embolic Protection System for the treatment of acute coronary syndromes.

As quoted in the press release:
Mr. Jaime Kehr, Chief Executive Officer of CorpMedical Chile Ltda, noted, “MGuard Prime™ with its MicroNet™ technology is

Licensed Producers Are Going Global, But This One Stands Out

Licensed Producers Are Going Global, But This One Stands Out

CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Harvest One Cannabis Inc.(TSXV:HVST) tremendous progress in growing its international footprint. The company’s wholly-owned United Greeneries subsidiary is awaiting approval from Health Canada for its ACMPR license to sell, but its

SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI).

The note is available here: DMPI October 2017 Update.

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)) is a clinical-stage biotechnology firm

Harvest One provides Update on subsidiary Satipharm and Sales License

Harvest One provides Update on subsidiary Satipharm and Sales License

Harvest One Cannabis Inc.(TSXV:HVST)  is pleased to provide a market update on its wholly owned subsidiary, Satipharm AG (“Satipharm”):

Satipharm has received German “Free Sales Certificate” reducing constraints for international export
Australian Regulatory Authority has issued final approval for CBD capsule prescription in Australia
Strong increase in European dietary supplement

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held October 1-4, 2017 in Pittsburgh, PA.  The poster entitled “Distinct mechanism of

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Vitality Biopharma Shares Results for Cannabinoid Drug Formulations

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/vitality-biopharma-shares-results-cannabinoid-drug-formulations/